肿瘤的节拍化疗

doi:10.3760/cma.j.issn.1673422X.2016.07.010

摘要/Abstract

摘要： 节拍化疗指以肿瘤内增殖的血管内皮细胞为靶点，通过持续应用低毒性剂量的药物而抑制肿瘤血管生成的一种化疗模式。节拍化疗在头颈部肿瘤、乳腺癌、消化道肿瘤、卵巢癌和前列腺癌中的成功应用显示了其潜在价值。节拍化疗的作用机制除抗肿瘤血管生成外，还包括刺激免疫和直接抗肿瘤效应，其与其他治疗模式的联合应用尚待深入探索。

关键词: 肿瘤, 药物疗法, 血管生成抑制剂

Abstract: Metronomic chemotherapy involves antiangiogenic processes that help host to fight against cancer by using continuous low dose drugs. Metronomic chemotherapy can be an effective treatment option for patients with head and neck carcinoma, breast cancer, gastrointestinal cancer, ovarian and prostate cancer. Metronomic chemotherapy also involves multiple mechanisms that include antiangiogenesis, immune stimulation and direct tumor cell targeting effects. We need to carefully evaluate the clinical effects of combination chemotherapies that incorporate the other treatment schedules.

Key words: Neoplasms, Drug therapy, Angiogenetic inhibitors

张百红, 岳红云. 肿瘤的节拍化疗[J]. 国际肿瘤学杂志, 2016, 43(7): 523-525.

ZHANG Bai-Hong, YUE Hong-Yun. Metronomic chemotherapy in human cancers[J]. Journal of International Oncology, 2016, 43(7): 523-525.

参考文献

［1］艾工文, 孟秀琴. 节律性化疗在血液肿瘤治疗应用的研究进展［J］. 现代肿瘤医学, 2015, 23(7): 10211024. DOI: 10.3969/j.issn.16724992.2015.07.40. ［2］ Patil VM, Noronha V, Joshi A, et al. A prospective randomized phase Ⅱ study comparing metronomic chemotherapy with chemotherapy (single agent cisplatin), in patients with metastatic, relapsed or inoperable squamous cell carcinoma of head and neck［J］. Oral Oncol, 2015, 51(3): 279286. DOI: 10.1016/j.oraloncology.2014.12.002. ［3］ Masuda N, Higaki K, Takano T, et al. A phase Ⅱ study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triplenegative or low hormone receptor expressing/HER2negative primary breast cancer［J］. Cancer Chemother Pharmacol, 2014, 74(2): 229238. DOI: 10.1007/s002800142492y. ［4］ Ferrandina G, Corrado G, Mascilini F, et al. Metronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter study［J］. BMC Cancer, 2014, 14: 947. DOI: 10.1186/1471240714947. ［5］ BarrosoSousa R, Da Fonseca LG, Souza KT, et al. Metronomic oral cyclophosphamide plus prednisone in docetaxelpretreated patients with metastatic castrationresistant prostate cancer［J］. Med Oncol, 2015, 32(1): 443. DOI: 10.1007/s1203201404434. ［6］ Derosa L, Galli L, Orlandi P, et al. Docetaxel plus oral metronomic cyclophosphamide: a phase Ⅱ study with pharmacodynamic and pharmacogenetic analyses in castrationresistant prostate cancer patients［J］. Cancer, 2014, 120(24): 39233931. DOI: 10.1002/cncr.28953. ［7］ Miger J, Holmqvist A, Sun XF, et al. Lowdose capecitabine (Xeloda) for treatment for gastrointestinal cancer［J］. Med Oncol, 2014, 31(3): 870. DOI: 10.1007/s1203201408702. ［8］ Alici S, Buyukberber S, Alkis N, et al. Lowdose docetaxel/cisplatinleucovorin and 46 hour infusional fluorouracil in metastatic gastric carcinoma［J］. Asian Pac J Cancer Prev, 2013, 14(1): 423427. ［9］ Brandi G, De Rosa F, Agostini V, et al. Metronomic capecitabine in advanced hepatocellular carcinoma patients: a phase Ⅱ study［J］. Oncologist, 2013, 18(12): 12561257. DOI: 10.1634/theoncologist.20130093. ［10］ Romiti A, Onesti CE, Roberto M, et al. Continuous, lowdose capecitabine for patients with recurrent colorectal cancer［J］. Med Oncol, 2015, 32(3): 54. DOI: 10.1007/s120320150496z. ［11］ Le DT, Jaffee EM. Regulatory Tcell modulation using cyclophosphamide in vaccine approaches: a current perspective［J］. Cancer Res, 2012, 72(14): 34393444. DOI: 10.1158/00085472.CAN113912. ［12］ Doloff JC, Waxman DJ. VEGF receptor inhibitors block the ability of metronomically dosed cyclophosphamide to activate innate immunityinduced tumor regression［J］. Cancer Res, 2012, 72(5): 11031115. DOI: 10.1158/00085472.CAN113380. ［13］ Yuan F, Shi H, Ji J, et al. Capecitabine metronomic chemotherapy inhibits the proliferation of gastric cancer cells through antiangiogenesis［J］. Oncol Rep, 2015, 33(4): 17531762. DOI: 10.3892/or.2015.3765. ［14］ Yi SY, Ruan J, Zhao L, et al. Metronomic gemcitabine targeted tumor vascular microenvironment decreases the population of CD133(+) cells in hepatocarcinoma xenografts［J］. Cancer Biomark, 2014, 14(6): 427433. DOI: 10.3233/CBM140419. ［15］ Srivastava K, Hu J, Korn C, et al. Postsurgical adjuvant tumor therapy by combining antiangiopoietin2 and metronomic chemotherapy limits metastatic growth［J］. Cancer Cell, 2014, 26(6): 880895. DOI: 10.1016/j.ccell.2014.11.005. ［16］ Berruti A, Fazio N, Ferrero A, et al. Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic welltomoderately differentiated neuroendocrine tumors: the XELBEVOCT study［J］. BMC Cancer, 2014, 14: 184. DOI: 10.1186/1471240714184. ［17］ Bazzola L, Foroni C, Andreis D, et al. Combination of letrozole, metronomic cyclophosphamide and sorafenib is welltolerated and shows activity in patients with primary breast cancer［J］. Br J Cancer, 2015, 112(1): 5260. DOI: 10.1038/bjc.2014.563. ［18］ Tupikowski K, Dembowski J, Kolodziej A, et al. Interferon alpha and metronomic cyclophosphamide for metastatic kidney cancer: a phase 2 study［J］. J Interferon Cytokine Res, 2015, 35(5): 367372. DOI: 10.1089/jir.2014.0106. ［19］ Zustovich F, Landi L, Lombardi G, et al. Sorafenib plus daily lowdose temozolomide for relapsed glioblastoma: a phase Ⅱ study［J］. Anticancer Res, 2013, 33(8): 34873494. ［20］ Barbolosi D, Ciccolini J, Meille C, et al. Metronomics chemotherapy: time for computational decision support［J］. Cancer Chemother Pharmacol, 2014, 74(3): 647652. DOI: 10.1007/s0028001425461. ［21］ André N, Banavali S, Snihur Y, et al. Has the time come for metronomics in lowincome and middleincome countries?［J］. Lancet Oncol, 2013, 14(6): e239e248. DOI: 10.1016/S14702045(13)700561. ［22］ Gnoni A, Silvestris N, Licchetta A, et al. Metronomic chemotherapy from rationale to clinical studies: A dream or reality?［J］. Crit Rev Oncol Hematol, 2015, 95(1): 4661. DOI: 10.1016/j.critrevonc.2015.01.008.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.